ImmunoPrecise Antibodies Ltd.
IPA
$3.20
$0.5721.67%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 88.28% | -663.46% | -5.32% | -14.05% | -242.71% |
| Total Depreciation and Amortization | -35.14% | 0.01% | 2.69% | -10.13% | 168.87% |
| Total Amortization of Deferred Charges | -100.00% | -- | -- | -- | -84.19% |
| Total Other Non-Cash Items | -96.62% | 3,176.24% | -298.93% | -143.28% | 409.84% |
| Change in Net Operating Assets | -125.04% | -23.59% | -202.13% | 66.73% | 91.10% |
| Cash from Operations | 31.16% | -10.74% | -12,251.13% | -221.38% | 29.36% |
| Capital Expenditure | 69.58% | -164.48% | 78.38% | -88.52% | -143.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 69.15% | -286.73% | 79.29% | -30.06% | -149.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -44.04% | -5.90% | -31.29% | 2.72% | 20.94% |
| Issuance of Common Stock | -98.81% | 1,044.81% | -- | -- | 142,400.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -135.54% | 1,534.60% | 763.73% | 748.52% | 394.21% |
| Foreign Exchange rate Adjustments | 75.86% | -73.42% | -101.77% | 62.29% | -7,438.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.97% | 4,720.00% | 46.83% | 128.55% | 9.99% |